SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The company witnessed a 9.49% growth in the revenue at Rs. 36687.00 millions for the quarter ended March 2022 as compared to Rs. 33507.00 millions during the year-ago period.Net Profit recorded in the quarter ended March 2022 rise to 34.74% to Rs. 4197.00  millions  compared to R. 3115.00 millions in corresponding previous quarter.Operating Profit saw a handsome growth to 7846.00 millions from 6845.00 millions in the quarter ended March 2022.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202203 202103 % Var 202203 202103 % Var 202203 202103 % Var
Sales 36687.00 33507.00 9.49 144052.00 133491.00 7.91 144052.00 133491.00 7.91
Other Income 1147.00 816.00 40.56 4820.00 8011.00 -39.83 4820.00 8011.00 -39.83
PBIDT 7846.00 6845.00 14.62 30761.00 39379.00 -21.88 30761.00 39379.00 -21.88
Interest 127.00 169.00 -24.85 380.00 467.00 -18.63 380.00 467.00 -18.63
PBDT 7719.00 6676.00 15.62 30381.00 38912.00 -21.92 30381.00 38912.00 -21.92
Depreciation 2052.00 2107.00 -2.61 8143.00 8350.00 -2.48 8143.00 8350.00 -2.48
PBT 5667.00 4569.00 24.03 22238.00 30562.00 -27.24 22238.00 30562.00 -27.24
TAX 1470.00 1454.00 1.10 6006.00 8698.00 -30.95 6006.00 8698.00 -30.95
Deferred Tax 496.00 666.00 -25.53 2080.00 3297.00 -36.91 2080.00 3297.00 -36.91
PAT 4197.00 3115.00 34.74 16232.00 21864.00 -25.76 16232.00 21864.00 -25.76
Equity 832.00 832.00 0.00 832.00 832.00 0.00 832.00 832.00 0.00
PBIDTM(%) 21.39 20.43 4.69 21.35 29.50 -27.61 21.35 29.50 -27.61

Dr. Reddys Labs. Share Price

1385.00 35.00 (2.59%)
29-Jun-2026 13:42 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1875.00
Dr. Reddys Labs. 1385.00
Cipla 1467.40
Zydus Lifesciences 1113.20
Lupin 2376.40
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: